Hepatitis C treatment outcome among people in prison: The SToP ‐C study
Liver International · 2024-11 · 44 (11) · 2996-3007
DOI: 10.1111/liv.16074 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Liver International, online erschienen am 27.08.2024. Verfasst von Hannah Ryan und 7 weiteren Autor:innen. Beteiligte Einrichtung: The Kirby Institute, UNSW Sydney, Sydney, New South Wales, Australia. Hauptthemen laut MEDLINE: Antiviral Agents, Sustained Virologic Response, Prisoners, Sofosbuvir. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Gilead Sciences, National Health and Medical Research Council.
Abstract (Originalsprache)
Background and Aims Hepatitis C virus (HCV) burden is higher among people in prison given high prevalence of injecting drug use. This study evaluated direct‐acting antiviral (DAA) treatment outcome in prisons.
Methods
The Surveillance and Treatment of Prisoners with hepatitis C (SToP‐C) study enrolled individuals incarcerated in four Australian prisons (2017–2019). Participants with detectable HCV RNA were offered sofosbuvir‐velpatasvir for 12 weeks. Sustained virological response (SVR) was assessed in intention‐to‐treat (ITT; participants commencing treatment and due for SVR assessment before study close) and per‐protocol (PP; participants with documented treatment completion and SVR assessment) populations.
Results
Among 799 participants with HCV, 324 (41%) commenced treatment (94% male; median age, 32 years; median duration of incarceration, 9 months). In ITT population ( n = 310), 201 had documented treatment completion (65% [95% CI: 59–70]), and 137 achieved SVR (ITT‐SVR: 44% [95% CI: 39–50]). In PP population ( n = 143), 137 achieved SVR (PP‐SVR: 96% [95% CI: 91–98]). Six participants had quantifiable HCV RNA at SVR assessment from treatment failure ( n = 2) or reinfection ( n = 4). Release or inter‐prison transfer was common reasons for no documented treatment completion ( n = 106/109 [97%]) and no SVR assessment ( n = 57/58 [98%]). In ITT analysis, longer incarceration was associated with increased SVR (adjusted OR per month 1.03 [95% CI: 1.01–1.04]).
Conclusion
Among participants who completed DAA treatment and were assessed for SVR, treatment outcome was consistent with non‐prison clinical studies. However, most individuals did not complete treatment or lacked study‐documented treatment outcome due to release or transfer. Strategies to accommodate dynamic prisoner populations are required to ensure continuity of HCV care, including treatment completion and post‐treatment care.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Kirby Institute, UNSW Sydney, Sydney, New South Wales, Australia.
ORCID-Profile: Hannah Ryan, Gregory J Dore, Jason Grebely, Evan B Cunningham, Marianne Martinello, Andrew R Lloyd, Behzad Hajarizadeh
Förderung
- Gilead Sciences
- National Health and Medical Research Council
Zitieren
APA
Ryan, H., Dore, G. J., Grebely, J., Byrne, M., Cunningham, E. B., Martinello, M., Lloyd, A. R., & Hajarizadeh, B. (2024). Hepatitis C treatment outcome among people in prison: The SToP ‐C study. Liver International, 44(11), 2996-3007. https://doi.org/10.1111/liv.16074
Vancouver
Ryan H, Dore GJ, Grebely J, Byrne M, Cunningham EB, Martinello M, et al. Hepatitis C treatment outcome among people in prison: The SToP ‐C study. Liver International. 2024;44(11):2996-3007. doi:10.1111/liv.16074
BibTeX
@article{Ryan2024,
author = {Ryan, Hannah and Dore, Gregory J and Grebely, Jason and Byrne, Marianne and Cunningham, Evan B and Martinello, Marianne and Lloyd, Andrew R and Hajarizadeh, Behzad},
title = {Hepatitis C treatment outcome among people in prison: The SToP ‐C study},
journal = {Liver International},
year = {2024},
volume = {44},
number = {11},
pages = {2996--3007},
doi = {10.1111/liv.16074}
}
EUVIMED